September 15, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – Escalation vs. Induction Treatment for Early MS Topic of Debate Two renowned multiple sclerosis (MS) specialistsĀ shared their opposing viewsĀ regarding the use of escalation or induction treatment for newly diagnosed MS patients. The debate was at the Hot Topic 1 Session of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 Congress, now taking place in London through…
September 15, 2016 News by Joana Fernandes, PhD #ECTRIMS2016 – New Data Show Ocrevus Effective in Treating Primary and Relapsing MS Positive new dataĀ from Phase 3 clinical trials assessingĀ Ocrevus (ocrelizumab) as a treatment for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) were recently announced by Roche, the company responsible for marketing and developing this investigationalĀ therapy. The results are being presented at the 32nd Congress of the…
September 14, 2016 News by Patricia Inacio, PhD #ECTRIMS2016 – Benefits of Gilenya in MS Also Appear Linked to Its Effects on B-Cells Scientists recently reported additional mechanisms of action that may underlieĀ Gilenya (fingolimod) beneficial effects in relapsing-remitting multiple sclerosis (RRMS). The results were in an oral presentation, āFingolimod therapy modulates B cell functions: reduces CXCR4-mediated migration and increases B cell -mediated anti-inflammatory cytokine profile,ā given atĀ theĀ 32nd Congress of theĀ European Committee for Treatment…
September 14, 2016 News by Patricia Inacio, PhD #ECTRIMS2016 – Cognitive Problems in MS Patients Linked to Lower Income, Study Reports In a recent talk, titled āIncome and cognitive impairment among multiple sclerosis patients,ā scientists investigated how cognitive impairmentĀ impacts the life of patients with multiple sclerosis (MS), and reported significant differences in incomeĀ that correlated with levels of MS-cognitive deficit. These findingsĀ were recently presented at the 32nd Congress of theĀ European Committee for…
September 14, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – Eye Imaging, Genetics Link Immune Complement Factors to MS Progression Genes that encode what are called “complement” immune factors are linked to the breakdown of the retina in multiple sclerosis (MS) patients ā a measure that, in turn, predicts brain damage and loss of eyesight. The study, a joint effort between researchers from Johns Hopkins School of Medicine,…
September 14, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – MS Care in Latin America Suffers from Lack of Healthcare Resources In a session titled “Challenges for care and research in MS outside Europe and North America” at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 CongressĀ Sept. 14-17 in London, researchers from Latin America shared the obstaclesĀ of scientists and multiple sclerosis (MS) patients in the…
September 14, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – MS Care and Research Lagging in Middle East, Experts Say Multiple sclerosis (MS) care and research is lagging behind in the Middle East compared to countries in Europe and North America, according to research presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 CongressĀ taking placeĀ in London through Sept. 17. Two presentations inĀ a session titled “…
September 14, 2016 Columns by admin #ECTRIMS2016 – Patient Empowerment Is One of My Highlights for Day 1 Europeās annual congress discussing treatment, including Patient Empowerment, and research in multiple sclerosis is now underway in London.Ā The 32ndĀ congress is being held from today until Saturday, when it draws to a close at lunchtime. The agenda is absolutely jammed full of topics being covered in a multitude of sessions…
September 14, 2016 News by Kara Elam #ECTRIMS2016 – Oryzon to Present Positive Preclinical Data on Potential MS Therapy Researchers from OryzonĀ will presentĀ efficacy data on the companyās oral epigenetic drugĀ ORY-2001, a potential treatment for multiple sclerosis (MS), at theĀ European Committee for Treatment and Research in Multiple SclerosisĀ (ECTRIMS) congress taking place this week in London. The poster presentation, āLSD1 inhibition, a potential epigenetic therapeutic approach for the…
September 14, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – Danish Children of MS Parents Perform Better Than Average in School Danish children of parents with multiple sclerosis (MS) are not hampered in their educational efforts by illness in the home,Ā according to a study findingĀ these children earned higher grades than their peersĀ through elementary and into their high school years. The study, āChildren of parents with multiple sclerosis attain higher…
September 12, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – Biogen to Unveil Study into Economic and Human Costs of MS At theĀ European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 Congress, taking placeĀ inĀ London on Sept. 14ā17, Biogen will present the Multiple Sclerosis Cost of Illness study, based on research intoĀ more than 16,000 MS patients throughout Europe. The study builds on data from a leading 2005 study that…
September 8, 2016 Columns by admin #ECTRIMS2016 – Stay Up to Date with My Pick of Congress Highlights The show comes to town in the next week with ECTRIMS hosting what it describes as āthe worldās largest annual international conferenceā devoted to basic treatment and clinical research in multiple sclerosis. It is being held in Londonās ExCel center from Wednesday to Saturday morning, and will be followed…
September 8, 2016 News by Charles Moore #ECTRIMS2016 – Congress on Latest in MS Research and Treatment Opens Sept. 14 The 32nd annual congress of the European Committee for Treatment and Research in Multiple Sclerosis, widely referred to as ECTRIMS, will kick off on Wednesday,Ā Sept. 14, in London. The four-day eventĀ is partnering this year with the Annual Conference of Rehabilitation in MS Ā (RIMS), the European network for best…
August 29, 2016 News by InĆŖs Martins, PhD Gilenya-like Therapy Shows Benefit in Secondary Progressive MS Patients in Phase 3 Trial Patients with secondary progressive multiple sclerosis (SPMS) who were treated with BAF312 (siponimod), a sphingosine-1-phosphate (S1P) inhibitor, in a Phase 3 clinical trial showed aĀ Ā significantly reduced risk for disability progression compared to placebo,Ā NovartisĀ recently announced. BAF312 is a selective modulator of specific types of the S1P receptor. This receptor is…